已收录 268921 条政策
 政策提纲
  • 暂无提纲
Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease
[摘要] Immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to chimeric antigen receptor T-cell therapy is common in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), but imaging findings during neurologic toxicity and their meaning have yet to be systematically described in this patient population. Brexucabtagene autoleucel (brexu-cel) is a CD19-directed autologous T-cell immunotherapy for the treatment of adult patients with R/R B-cell ALL that can enter the central nervous system. We present a case of an adult patient with R/R B-cell ALL and prior leptomeningeal disease who developed neurologic toxicity and new findings on magnetic resonance imaging of the brain while receiving brexu-cel. We interpret the patient's neuroimaging studies within clinical context to differentiate ICANS from active treatment of residual leukemia.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 生物化学工程
[关键词] CD-19-targeted chimeric antigen receptor T-cell therapy;B-cell acute lymphoblastic leukemia;Immune effector cell-associated neurotoxicity syndrome;Magnetic resonance imaging of the brain;Cerebrospinal fluid [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文